— Know what they know.
Not Investment Advice

BSEM NASDAQ

BioStem Technologies, Inc.
1W: -34.1% 1M: -22.9% 3M: -25.4% YTD: -30.4% 1Y: -45.3% 3Y: +11.4% 5Y: +110.0%
$2.73
-0.34 (-11.07%)
 
Weekly Expected Move ±16.0%
$2 $2 $3 $3 $4
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 30 · $46.4M mcap · 13M float · 0.772% daily turnover · Short 35% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$46.4M
52W Range2.25-8.4
Volume157,702
Avg Volume96,790
Beta0.26
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJason Matuszewski
Employees73
SectorHealthcare
IndustryBiotechnology
IPO Date2015-03-17
4901 Northwest 17th Way
Fort Lauderdale, FL 33309
US
954 380 8342
About BioStem Technologies, Inc.

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Recent Insider Trades

NameTypeSharesPriceDate
SMITH-VAN VURST ANDR M-Exempt 9,574 — 2026-09-17
SMITH-VAN VURST ANDR M-Exempt 9,574 — 2026-09-17
Matuszewski Jason M-Exempt 16,650 — 2026-09-17
Matuszewski Jason M-Exempt 16,650 — 2026-09-17
POE BRANDON M-Exempt 1,694 — 2026-09-15

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms